Clinical trial
Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
NCT03471624 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)
- Lead sponsor
- Stanford University
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- May 1, 2018
- Completion date
- April 19, 2022
- Enrollment
- 270 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.